GLP-1 Receptor Agonists and Dementia Risk in Older Adults With Type 2 Diabetes: Insights From a Target Trial Emulation
Highlight
– In a target trial emulation of U.S. Medicare beneficiaries, GLP-1 receptor agonists (GLP-1RAs) did not show a statistically significant reduction in incident dementia compared to DPP-4 inhibitors (DPP4is) overall.
– Age-stratified analysis suggested possible benefit for those under 75 years (risk ratio 0.64; 95% CI, 0.46–0.93) but no benefit—and perhaps harm—in those 75 or older (risk ratio 1.22; 95% CI, 0.74–1.66).
– The study underscores the need for randomized controlled trials to clarify the cognitive effects of GLP-1RAs in diabetes care.
Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.